ILUVIEN patient case study library Phakic Eye Treatment Burden Managing IOP Vitrectomized Case 3 years of Iluvien 3 years of ILUVIEN Results presented below are from a single case; results may vary. After treatment with ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, retinal edema was stabilized in this patient This case was collected in Europe The patient was treated with ILUVIEN® 190 micrograms intravitreal implant in applicator The patient met the US labeling requirements in that they were previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP In Europe, ILUVIEN is approved for the treatment of visual impairment due to chronic DME Patient profile1 Sex: Male Age: 64 Diagnosis: DME Treated eye: OS Concomitant conditions: None Treatment history: • 1x Corticosteroid Notes: Pseudophakic 36-month follow-up of CST and VA in a single eye (OS) of a 64-year-old pseudophakic patient (n=1) USERSTUDYReal-world data from the USER Study confirm the efficacy of ILUVIEN. SEE THE DATAReal-worldSAFETYThe USER Study confirms the predictable IOP profile of ILUVIEN, when used per label. SEE THE DATA